Progression of IgA nephropathy under current therapy regimen in a chinese population

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 3, 2014, Pages 484-489

  Li, Xiangling ^a,b,c,d   Liu, Youxia ^a,b,c   Lv, Jicheng ^a,b,c   Shi, Sufang ^a,b,c   Liu, Lijun ^a,b,c   Chen, Yuqing ^a,b,c   Zhang, Hong ^a,b,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

^d WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; PREDNISONE; STEROID; URIC ACID; VITAMIN D;

ADOLESCENT; ARTERIAL PRESSURE; ARTICLE; CHINA; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CHINA; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; STEROIDS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896840943     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01990213     Document Type: Article

References (36)

1. Berger J, Hinglais N: Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris) 74: 694-695, 1968
2. D'Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 64: 709-727, 1987
3. Donadio JV, Grande JP: IgA nephropathy.NEngl J Med 347: 738-748, 2002
4. D'Amico G: Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: Survey of the recent literature. Am J Kidney Dis 20: 315-323, 1992
5. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L: Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22: 752-761, 2011
6. Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, Ren H, Pan X, Chen X, Zhang W, Li X, Shi H, Li Y, Gharavi AG, Chen N: Predicting progression of IgAnephropathy: Newclinical progression risk score. PLoS One 7: e38904, 2012
7. Rauta V, Grönhagen-Riska C: IgA nephropathy: From predicting progression to treatment. Duodecim 122: 215-222, 2006
8. Koyama A, Igarashi M, Kobayashi M; ResearchGroup on Progressive RenalDiseases: Natural historyand risk factors for immunoglobulinA nephropathy in Japan. Am J Kidney Dis 29: 526-532, 1997
9. Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y: A scoring system to predict renal outcome in IgA nephropathy: A nationwide 10-year prospective cohort study. Nephrol Dial Transplant 24: 3068-3074, 2009
10. Kiryluk K, Novak J, Gharavi AG: Pathogenesis of immunoglobulin A nephropathy: Recent insight from genetic studies. Annu Rev Med 64: 339-356, 2013
11. Mestecky J, Raska M, Julian BA, Gharavi AG, Renfrow MB, Moldoveanu Z, Novak L, Matousovic K, Novak J: IgA nephropathy: Molecular mechanisms of the disease. Annu Rev Pathol 8: 217-240, 2013
12. Kataoka H, Ohara M, Shibui K, Sato M, Suzuki T, Amemiya N, Watanabe Y, Honda K, Mochizuki T, Nitta K: Overweight and obesity accelerate the progression of IgA nephropathy: Prognostic utility of a combination of BMI and histopathological parameters. Clin Exp Nephrol 16: 706-712, 2012
13. Syrjänen J, Mustonen J, Pasternack A: Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 15: 34-42, 2000
14. Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, Liu Z: Long-term renal survival and related risk factors in patients with IgA nephropathy: Results froma cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 27: 1479-1485, 2012
15. Bartosik LP, Lajoie G, Sugar L, CattranDC: Predicting progression in IgA nephropathy. Am J Kidney Dis 38: 728-735, 2001
16. Ballardie FW: Quantitative appraisal of treatment options for IgA nephropathy. J Am Soc Nephrol 18: 2806-2809, 2007
17. Lv J, Xu D, Perkovic V, Ma X, Johnson DW, Woodward M, Levin A, Zhang H, Wang H; TESTING Study Group: Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 23: 1108-1116, 2012
18. Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H: Combination therapy of prednisone and ACE inhibitor versus ACEinhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 53: 26-32, 2009
19. Abreo K, Wen SF: A case of IgA nephropathy with an unusual response to corticosteroid and immunosuppressive therapy. Am J Kidney Dis 3: 54-57, 1983
20. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2: 139-274, 2012
21. Reich HN, Troyanov S, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry: Remission of proteinuria improves prognosis in IgA nephropathy. J AmSoc Nephrol 18: 3177-3183, 2007
22. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
23. Wang H, Lv J, Zhang H: Evaluation of the treatment of adult IgA nephropathy from the perspective of evidence-based medicine. Chin J Intern Med 43: 712-714, 2004
24. Ballardie FW, Roberts IS: Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J AmSoc Nephrol 13: 142-148, 2002
25. Haas M: Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases. Am J Kidney Dis 29: 829-842, 1997
26. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDMwith the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18: 1540-1546, 2007
27. Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, Gharavi AG, Novak J, Zhang H: The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 82: 790-796, 2012
28. Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J: Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23: 1579-1587, 2012
29. Mackinnon B, Fraser EP, Cattran DC, Fox JG, Geddes CC: Validation of the Toronto formula to predict progression in IgA nephropathy. Nephron Clin Pract 109: c148-c153, 2008
30. Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY: Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: A randomized controlled trial. AmJ Kidney Dis 59: 67-74, 2012
31. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK: Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: An uncontrolled trial. Am J Kidney Dis 51: 724-731, 2008
32. Kuemmerle NB, Krieg RJ Jr., Chan W, Trachtman H, Norkus EP, Chan JC: Influence of alpha-tocopherol over the time course of experimental IgA nephropathy. Pediatr Nephrol 13: 108-112, 1999
33. Chan W, Krieg RJ Jr., Norkus EP, Chan JC: alpha-Tocopherol reduces proteinuria, oxidative stress, and expression of transforming growth factor beta 1 in IgA nephropathy in the rat. Mol Genet Metab 63: 224-229, 1998
34. Ong-ajyooth L, Ong-ajyooth S, Parichatikanond P: The effect of alpha-tocopherol on the oxidative stress and antioxidants in idiopathic IgA nephropathy. J Med Assoc Thai 89[Suppl 5]: S164-S170, 2006
35. Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ: Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol 13: 2916-2929, 2002
36. Moura IC, Arcos-Fajardo M, Sadaka C, Leroy V, Benhamou M, Novak J, Vrtovsnik F, Haddad E, Chintalacharuvu KR, Monteiro RC: Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J AmSoc Nephrol 15: 622-634, 2004